Latest Proton pump inhibitors Stories

THE WOODLANDS, Texas, May 15, 2012 /PRNewswire/ -- Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients....

DEERFIELD, Ill., May 2, 2012 /PRNewswire/ -- Celebrity chef Spike Mendelsohn knows all too well the effects of a busy and hectic lifestyle - especially for a person with acid reflux disease (ARD). But while he's used to firing up the grill, Chef Spike has also had to learn how to turn down the heat on his heartburn associated with ARD. To raise awareness and understanding about the importance of managing heartburn symptoms of ARD, including through lifestyle modifications,( )Chef...

On February 8th, 2012 the U.S. FDA issued a warning on drugs called proton pump inhibitors (PPIs) – including Prilosec - that might increase the risk of a type of chronic diarrhea and lead to severe intestinal problems and, in rare cases, death. Prilosec is a proton pump inhibitor (PPI) prescribed to treat acid reflux, stomach ulcers and other conditions. Moreover, in May 2010, the FDA announced that the safety labeling for proton pump inhibitors would be updated to include information...

RIDGEFIELD, Conn., Feb. 3, 2012 /PRNewswire/ -- Boehringer Ingelheim presented results of a drug interaction study that found Aggrenox® (aspirin/extended-release dipyridamole), an antiplatelet medication, is not affected by the co-administration of omeprazole, a proton pump inhibitor (PPI), frequently used to treat several gastrointestinal conditions. These data were presented at the International Stroke Conference (ISC) in New Orleans. "Omeprazole has been shown to interact with...

Asthma and gastroesophageal reflux (GER) are both common illnesses in children. GER in children often occurs without the typical symptoms of heartburn, and physicians frequently prescribe the acid reflux drug lansoprazole to supplement the standard inhaled steroid treatment for children with uncontrolled asthma regardless of GER symptoms. However, a randomized clinic trial conducted by the American Lung Association's Asthma Clinical Group found that the addition of lansoprazole does not...

Children without symptoms of gastroesophageal reflux whose asthma was being poorly controlled with anti-inflammatory treatment did not have an improvement in symptoms or lung function with the added treatment of the proton pump inhibitor lansoprazole, compared to patients who received placebo, according to a study in the January 25 issue of JAMA. Use of lansoprazole was associated with increased adverse events. "Asthma and gastroesophageal reflux (GER) disease are both common disorders in...

WOBURN, Mass., Jan. 19, 2012 /PRNewswire/ -- CutisPharma, Inc. announced the introduction of FIRST® - Omeprazole and FIRST® - Lansoprazole Unit-of-Use oral suspension compounding kits. These new kits will help pharmacists dispense these compounded prescriptions containing widely used proton pump inhibitors (PPIs). Traditionally, compounded omeprazole and lansoprazole oral suspensions can take up to several hours to prepare and are quite unpleasant to the taste. With FIRST®...

Oseltamivir. Esomeprazole. Trastuzumab. Where do drugs get those odd-sounding generic names? The answers are in the current issue of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, the world's largest scientific society, which explains the logic behind the tongue-twisters. C&EN Associate Editor Carmen Drahl explains that until 1961 there was no standard for assigning drugs generic names, which are different from brand names like...

Takeda Pharmaceuticals North America, Inc., (Takeda) announced the DEXILANT (dexlansoprazole) product labeling now includes information from a study in healthy subjects demonstrating that DEXILANT had no clinically important effect on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition. No dose adjustment of clopidogrel is necessary when administered with an approved dose of DEXILANT. DEXILANT is a proton pump inhibitor (PPI) indicated for the...

DEERFIELD, Ill., Nov. 17, 2011 /PRNewswire/ -- Today, Takeda Pharmaceuticals North America, Inc., (Takeda) announced the DEXILANT (dexlansoprazole) product labeling now includes information from a study in healthy subjects demonstrating that DEXILANT had no clinically important effect on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition. No dose adjustment of clopidogrel is necessary when administered with an approved dose of DEXILANT. DEXILANT is a...